As the field of medical research accelerates, stem cell technology stands at the forefront of innovative treatment options and scientific discovery. The global stem cell market is projected to surpass significant financial milestones, making it a hot topic in both the scientific community and the business world. For students contemplating careers in science, technology, engineering, and mathematics (STEM), this growing market offers both exciting possibilities and serious considerations as they shape their educational paths. [Read more…]
What are Perinatal Stem Cells? Your Definitive Guide
Perinatal stem cells are obtained around the time of birth, either shortly before or after. They can be sourced from umbilical cord blood and tissue, placental blood and tissue, as well as amniotic fluid and tissue.
When stem cells were first identified, only two types of stem cells were described: embryonic stem cells and adult stem cells. Today, a diverse range of stem cells exist, because the diversity of adult stem cell types has substantially expanded and induced pluripotent stem cells (iPSCs) have since been discovered. [Read more…]
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease
A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer (NK) therapy in an autoimmune disease. The product, known as QN-139b, was administered to a patient with refractory systemic sclerosis (SSc), marking the first time an iPSC-derived CAR immune therapy has been used beyond oncology. [Read more…]
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA.
Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioactive material fields. [Read more…]
HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders
Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases. [Read more…]
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 202
- Next Page »